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ABSTRACT
Objectives: There exists a lack of extrapolation methods for
long-term survival analysis when censored rates are high
(25–50%). This study aimed at estimating life expectancy
(LE) after the diagnosis of cancer and the expected years of
life lost (EYLL) using a newly developed semiparametric
method.
Methods: Patients (n = 425,294) diagnosed with 17 different
types of major cancer were enrolled. All of the patients were
registered with the Taiwan Cancer Registry between 1990
and 2001; their survivals were followed through the end of
2004. The survival function for an age- and sex-matched
reference population was generated using the Monte Carlo
method from the life table of the general population. Lifetime
survival of the cancer patients (up to 50 years) were obtained
using linear extrapolation of a logit-transformed curve of the
survival ratio between the cancer and reference populations.
The estimates were compared with the results from the
extrapolation of ﬁtted Weibull models.
Results: The 15-year survival, LE, and EYLL for 17 different
types of cancer were determined, of which the LE of breast,
cervical, ovarian, and skin cancers exceeded 15 years;
nasopharyneal, leukemia, bladder, kidney, and colorectal
cancers exceeded 10 years. Validity tests indicated that the
relative biases of the extrapolated estimates were usually
<5% under high censoring rates.
Conclusions: The newly developed method is feasible and
relatively accurate to project LE and EYLL, which could also
be merged with data pertaining to quality of life, for a more
detailed outcome assessment in the future.
Keywords: life expectancy, lifetime extrapolation, Monte
Carlo method, survival, years of life lost.
Introduction
Cancer is an issue of major public health concern, not
only because it can cause substantial suffering and
shorten the natural lifespan of cancer patients, but also
because of the signiﬁcant impact it can have upon
society as a whole [1]. The estimation of life expectancy
(LE) from the date the diagnosis of cancer is made until
death has been performed in many medical ﬁelds to
generate measures of cancer survival relevant to clini-
cians, health economists, policymakers, and insurance
companies [2]. In general, survival analysis provides an
estimation of the survival rate during the observed
study period, but there has been a lack of reliable
method for lifetime extrapolation [3]. Parametric sur-
vival modeling, such as the Weibull distribution [4],
Gompertz extrapolation technique [5,6], exponential
distribution [7], and the log-normal distribution [8], are
commonly used for lifetime extrapolation; however, the
models may not be suitable for data with a high rate of
right censoring, such as patients infected with human
immunodeﬁciency virus [9].
We have developed a semiparametric method to
incorporate LE information of the general population
into the estimation process [9–14]. If the cancer-related
excess hazard assumes constant after a period of time,
cancer patients’ LE can be projected from the available
follow-up data with this semiparametric method [10].
In addition to estimating the LE after diagnosis, the
method can also be used to compute the expected years
of life lost (EYLL), which is a measure of the overall
burden on individuals and on society as a whole [1],
and a more accurate reﬂection of the social and eco-
nomic impact of cancer than that provided by crude
incidence rates or mortality data [15]. Moreover, a
valid estimation of LE and EYLL in cancer patients is
crucial for the outcome assessment of effectiveness for
cancer management and resource allocation of health
services [3,16,17].
Using the data from the National Cancer Registry
and vital statistics, we sought to estimate the mean
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lifetime survival duration and EYLL for the major
types of cancer in Taiwan. The estimates were com-
pared with the results obtained from parametric sur-
vival modeling.
Methods
Cancer Cohorts
The Taiwan National Cancer Registry, with a total of
425,294 patients diagnosed with 17 major cancers
between 1990 and 2001, was the primary data source
for this study. The anatomic sites of the 17 major
cancers included the oral cavity, nasopharynx, esopha-
gus, stomach, colon and rectum, liver, gallbladder and
extrahepatic bile ducts, pancreas, lung, leukemia, skin,
breast, cervix, ovary, prostate, bladder, and kidney and
other urinary organs.
Survival in the Cancer Populations
Each cancer patient was followed through the end of
2004, and the survival status of each patient was
further veriﬁed by cross-checking with the national
mortality certiﬁcation database maintained by Tai-
wan’s Ministry of the Interior [18]. We used the
Kaplan–Meier method to estimate survival function
based on the follow-up data from 1990 to 2004.
Extrapolation of Long-Term Survival for the Cancer
Population after Follow-Up Limit
The detailed method, including the technical details
and its proof, can be found in our previous articles
[9,10]. The main idea of this approach is to borrow
information from a reference population, of which the
survival time is obtained from the available data of the
national life table. Brieﬂy, the extrapolation process
comprised of three phases. First, we created a reference
population of subjects whose age and sex matched
with the cancer patients. The survival times of the
reference population were generated from a general
population with known survival times, using the
Monte Carlo method. Second, we ﬁtted a simple linear
regression to the logit transform of the survival ratio
between the cancer population and the reference popu-
lation up to the end of the follow-up period. Finally,
the estimated regression line and survival curve of the
reference population was used to project a long-term
survival curve beyond the follow-up limit. We pre-
sented the major procedures of the method below.
Survival in the Reference Population
The life tables for the general population were
obtained from the national vital statistics, as published
by the Department of Statistics, Ministry of the Inte-
rior, Executive Yuan, Taiwan. Because the individual
survival time of the subjects in a hypothetical cohort
cannot be directly derived from the life table of the
general population, we used the Monte Carlo method
to generate the simulated survival time of age- and
sex-matched hypothetical subjects for each patient in
the cancer cohorts. And the total collection of hypo-
thetical subjects was used as the reference population.
Then, the survival curve of the reference population is
obtained by applying the Kaplan–Meier method to the
simulated survival times [10].
Logit Survival Ratio Extrapolation
The semiparametric method was used to extrapolate
the survival time beyond the follow-up limit of 15
years. The survival ratio between the survival func-
tions of two populations is deﬁned by the formula:
W t S t
S t
( ) = ( )
( )
patient population
reference population
Because the cancer population has a worse survival
than the reference population, the value of survival
ratio, W(t), initially equals 1, then gradually decreases
due to disease-associated excess mortality. Because the
value of W(t) is limited to the range from 0 to 1, linear
regression for the temporal trend is not applicable.
We therefore used the logit transformation of W(t).
Furthermore, if the cancer-associated excess hazard
remains constant over time, the curve of the logit of
W(t) will converge to a straight line.
We then ﬁtted a simple linear regression for the logit
of W(t) from the time point, which was usually after
the unstable period (e.g., initial active diagnostic or
therapeutic management) to the end of the follow-up.
Finally, given the least squares estimates of the inter-
cept and slope parameters, αˆ and βˆ, we projected the
long-term survival curve of the patient population
beyond the follow-up limits as:
ˆ
ˆ ( ˆ
ˆ
S t
S t
t
patient population
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1 exp(+ +ˆ ˆ )
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α βt
The standard error of survival estimates was obtained
through a bootstrap method by implementing the
extrapolation process with data simulated by repeat-
edly sampling techniques with replacement from a real
data set 300 times [9,10,14]. To facilitate the compu-
tation, we developed a software program, MC-QAS,
which was built in the R statistical package, which can
be freely downloaded from http://www.stat.sinica.edu.
tw/jshwang.
Estimation of EYLL
The average EYLL of a cancer cohort was deﬁned in
this study as the mean survival difference between the
speciﬁc cancer cohort and an age- and sex-matched
reference population. In other words, the average
EYLL was the difference in the area between the mean
survival curves of the cancer and reference popula-
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tions. This parameter provides us with a measure of
the burden of cancer on individual patients and yields
an estimation of how much a patient’s life is likely to
be shortened by cancer [16]. The average EYLL was
then multiplied by the total annual incidences of
cancer for each cancer site in 1 year to obtain the
subtotal of EYLL for the year; clearly, the subtotal of
EYLL can be regarded as an indicator of the total
burden of cancer on society as a whole [1].
Validation of the Monte Carlo Extrapolation and
Comparison with the Parametric Method
Empirical cancer data from the National Cancer Reg-
istry provided us with an opportunity to validate
actual performance. Thus, a selected subcohort of
patients diagnosed between 1990 and 1996 with those
cancers of interest to this study was created for each
cancer site. It was assumed that the cohorts were only
followed up until the end of 1996, or for a period of 7
years. We extrapolated the data through the end of
2004 using both the Monte Carlo method and the
Weibull model for comparison. For every subcohort
that was followed up until the end of 2004, the
Kaplan–Meier method was calculated as the “gold
standard” to determine the accuracy. The relative
biases for each cancer site were also computed to
compare the differences in values between the Kaplan–
Meier estimates and the two extrapolation methods.
Results
LE and EYLL
The 15-year follow-up data were used to extrapolate
the lifetime survival time to the 50th year after diag-
nosis for the estimation of the LE. The Kaplan–Meier
estimate was applied to estimate the mean survival
time in the 15-year follow-up. The LE and EYLL for
the 17 major cancer sites are summarized in Table 1.
The censoring rates for the survival analysis were
between 8% and 67% by the end of the 15-year
follow-up period. In terms of population sizes, liver
cancer had the largest cohort, while gallbladder and
extrahepatic bile duct cancers had the smallest cohort.
We found that the cohorts with the longest LE were
breast (20.01 years), cervical (19.77 years), and
ovarian cancers (17.71 years), and the shortest LE
were pancreatic (2.81 years), lung (3.09 years), and
liver cancers (3.45 years). The estimated average EYLL
of a cancer cohort is the difference between the areas of
estimated survival curves for the reference population
and the cancer cohort. As an example shown in Fig. 1,
estimated EYLL for a gastric cancer patient was 8.8
years. The cohorts with the largest average estimated
EYLL were leukemia (19.34 years) and cancers of the
liver (15.61 years) and nasopharynx (14.79 years).
Following multiplication by the total annual inci-
dences for the different types of cancer in 2001, the
greatest health impacts on society, in terms of the
subtotal of EYLL for the year, were cancers of the liver,
lung, and oral cavity. Furthermore, the average
expected life span could be obtained simultaneously
after the consideration of the mean age at diagnosis
and the mean LE after diagnosis. The patterns of the
average expected life spans for the different types of
cancer were different from those of LE using our
method and are listed in Fig. 2. Leukemia (53.41
years), and cancers of the nasopharynx (62.19 years)
and oral cavity (63.38 years), had the shortest average
expected life span.
Validity of Extrapolation
The cancer cohorts established during the 7 years
between 1990 and 1996 were extrapolated to an addi-
tional 8 years and were then compared with actual
survival estimated with the Kaplan–Meier method
using the complete 15 years of follow-up, from 1990
to 2004. The calculations of the relative biases for the
two methods are summarized in Table 2. The censor-
ing rates at the end of the ﬁrst 7-year follow-up period
ranged between 21% and 81%. The absolute values of
the relative biases for the Monte Carlo method ranged
between 0.76% and 14.41% after 8 years of extrapo-
lation; these values were generally much smaller than
those obtained under the Weibull model, with the
notable exceptions of skin and prostate cancers. Nev-
ertheless, the standard errors for the Weibull model
were generally smaller than those for the Monte Carlo
method. There are some variations or differences
between the Kaplan–Meier estimates in Tables 1 and 2
because they were calculated from two different
periods of cohorts of cancer, namely, those diagnosed
during 1990 to 2001 and 1990 to 1996, respectively.
Discussion
The method adopted for this study incorporated data
simultaneously from the mortality patterns of the
general population based on vital statistics and actual
experience of the cancer patients, which would be
better than potential years of life lost, assuming an
arbitrarily chosen potential limit of life such as 65
years [19]. Moreover, the method can estimate the
lifetime survival for different types of cancer with a
reasonable accuracy after about 7 years of follow-up,
as shown in Table 2.
Some researchers assume that the survival of cancer
patients at the end of follow-up is similar to that in the
general population [2], such as children with acute
lymphoblastic leukemia, who may enjoy an event-free
survival for longer than 10 years [20]. In fact, the
above assumption can be regarded as a special case in
this method with the excess hazard presumed to be 0
after an initial period of treatment, and it was also
applicable in other diseases, such as long-term survival
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after a head injury [21]. There are other methods
dealing with censoring, which can be applied under
different circumstances [22,23]. Nevertheless, the
method proposed by us directly extrapolates the unﬁn-
ished survival curves to lifetime and seems the most
straightforward both in concept and in actual clinical
practice for following up cancer cohorts, as our
method only relies on the availability of vital statistics
of the general population and an assumption of con-
sistent premature mortality throughout lifetime.
In cost-effectiveness analyses, the Markov model is
often applied to estimate LE, which uses a ﬁnite number
of the hypothetical cohort to simulate effectiveness
(e.g., survival) and cost, but requires external data
and/or methods to facilitate the sensitivity analysis on
some assumptions. Our method, which is based on the
actual cohort data of follow-up, could be used to vali-
date the results from the Markov model [9]. In fact, the
result of the long-term survival (40 years) for breast
cancer cohort in this study is similarwith those based on
a simulation from theMarkovmodel, with andwithout
treatment of trastuzumab [24], as shown in Fig. 3.
The method may also be applied in clinical trials, in
which at least two arms or cohorts of patients, say,
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Figure 1 Mean survival difference between
gastric cancer population and reference popu-
lation after 50 years of extrapolation.
0
10
20
30
40
50
60
70
80
90
Le
uk
em
ia
Na
so
ph
ar
yn
x
Or
al 
ca
vit
y
Liv
er
Es
op
ha
gu
s
Ov
ar
y
Pa
nc
re
as
Lu
ng
Br
ea
st
Ga
llb
lad
de
r &
 e
xtr
ah
ep
at
ic 
bil
e 
du
ct
St
om
ac
h
Ki
dn
ey
 &
 o
th
er
 u
rin
ar
y o
rg
an
s
Ce
rv
ix 
ut
er
i
Co
lon
 &
 re
ctu
m
Bl
ad
de
r
Sk
in
Pr
os
ta
te
Cancer type
A
ve
ra
ge
 e
xp
ec
te
d 
lif
e 
sp
an
 in
 y
ea
rs
Mean age at diagnosis Life expectancy after diagnosis
Figure 2 Average expected life span by cancer type. Estimates are shown as the sum of mean age at diagnosis and life expectancy after diagnosis.
1106 Chu et al.
treatment versus placebo, are followed for a period
of time to observe their actual survival and qua-
lity of life. Thus, we would obtain two survival
ratios, S(t|treatment)/S(t|reference) and S(t|placebo)/
S(t|reference), at a different time t and they both could
be extrapolated to lifetime with conﬁdence intervals
obtained through the bootstrap method for compari-
son [10]. Our method does not need to classify the
study disease into a limited number of health states to
obtain the transition probabilities. Instead, the quality
of life data collected during clinical trials at each time
t can provide the mean value that can be directly
multiplied with the survival probability and summed
up to obtain the quality-adjusted LE [12].
Based on our results, the methodology presented
here could be more useful for cancer or some diseases
in which survival is longer or prognoses are better, or
there is a high censoring rate at the end of the follow-
up, such as cancers of the breast, cervix, ovary, and
nasopharynx. Furthermore, the incidence rates of the
cancers of the oral cavity and breast have increased
recently in Taiwan [25] and the ages at diagnosis are
about 50 years of age, which is earlier than other
common cancers, as shown in Fig. 2. From the results
of this study, oral cancer had a large average EYLL
(14.00 years) and subtotal of EYLL (49,671 years),
and breast cancer also had a large subtotal of EYLL
(43,633 years). Thus, we recommend that policymak-
Table 2 Estimates of mean survival years in 15 years of follow-up using the Monte Carlo method and theWeibull model approaches
on the ﬁrst 7 years of follow-up data with high censored rates were compared with the Kaplan–Meier estimates based on 15 years of
follow-up
Cancer site
15-year follow-up Extrapolation based on the ﬁrst 7-year follow-up
Kaplan–Meier estimate Monte Carlo method Weibull model
Censoring rate (%)Estimates Estimates SE Relative bias (%) Estimates SE Relative bias (%)
Colon and rectum 7.12 7.06 0.14 -0.76 6.40 0.06 -10.07 62.73
Leukemia 4.99 5.05 0.17 1.19 4.10 0.11 -17.83 43.41
Skin 9.74 9.85 0.28 1.21 9.71 0.14 -0.26 80.53
Bladder 7.76 7.66 0.27 -1.25 7.38 0.12 -4.81 68.21
Stomach 4.82 4.93 0.08 2.19 3.78 0.05 -21.61 42.85
Cervix uteri 10.10 9.82 0.16 -2.82 9.01 0.09 -10.84 77.69
Breast 10.03 9.73 0.18 -2.99 8.93 0.10 -10.98 80.52
Esophagus 2.59 2.68 0.1 3.58 1.73 0.05 -33.02 27.91
Ovary 8.38 8.70 0.25 3.89 7.47 0.18 -10.87 67.34
Kidney and other urinary
organs
7.10 6.75 0.24 -4.92 6.51 0.14 -8.33 62.34
Oral cavity 5.68 5.38 0.17 -5.38 4.43 0.07 -21.94 54.28
Prostate 6.73 6.30 0.32 -6.44 6.37 0.14 -5.28 68.85
Gallbladder and
extrahepatic bile duct
3.59 3.82 0.19 6.57 2.63 0.11 -26.77 33.62
Pancreas 2.09 2.24 0.13 6.73 1.23 0.04 -41.21 20.89
Nasopharynx 7.10 6.55 0.24 -7.71 5.86 0.10 -17.41 62.52
Lung 2.38 2.57 0.05 8.00 1.62 0.02 -31.77 25.18
Liver 2.48 2.83 0.08 14.41 1.81 0.02 -26.70 27.58
The censoring rates were computed at the end of the ﬁrst 7-year follow-up period.
SE, standard error.
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Figure 3 Long-term survival curve for
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inTaiwan using the Monte Carlo method,which
was compared with published [24] survival
curves of patients with early breast cancer
simulated under the Markov model with and
without treatment of trastuzumab.
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ers place the prevention of major causes of oral cancer,
such as betel quid chewing, tobacco usage, and excess
consumption of alcohol [26], at a higher priority. The
screening program for breast cancer should be targeted
to an earlier age group, such as the 40 to 49 years of
age group, to possibly save more life years.
Although we have used the best national data cur-
rently available in Taiwan, the study still had some
limitations that need to be addressed before wide
adoption for outcome evaluation. The ﬁrst limitation
of the method was the uncertainty regarding the sta-
bility of excess hazard in the extrapolation period.
Because the cancer-related excess hazard is unlikely
to be exactly constant throughout the extrapolation
period, a certain degree of prediction error is unavoid-
able [10]. In spite of the uncertainty, our semiparamet-
ric method avoids the large deviations in long-term
projections seen with the parametric model, such as
under the Weibull distribution, with the advantage of
an input of information from the life table of the
background general population. Even if the assump-
tion of a constant excess hazard between the cancer
and reference populations may not hold, the method
used the median of slopes near the end of the follow-
up, which was generally the least biased in the extrapo-
lation [9,10,14]. Excluding those cancers with a low
censoring rate, i.e., <25%, for which there is usually
less need for a long period of extrapolation, the rela-
tive biases were usually <5.0%. The second limitation
was that the extrapolation method required an
assumption of premature mortality, which does not
hold for skin cancer, and is therefore, slightly less
accurate. Third, the lifetime extrapolation is based on
current and prior experiences, such as life tables;
however, it is clear that such a method could easily
underestimate the actual survival of future cancer
populations because it does not consider the active
development and adoption of newer technologies for
cancer diagnosis and management. Thus, our estima-
tion of lifetime survival of cancer patients may be a
conservative one, while the EYLL could easily be over-
estimated. Finally, because LE is also a function of
comorbidity, disability, and cancer stage, in addition to
age and cancer type [27], the current estimate provides
only a rough estimation of the average loss of LE. It
may be possible, in future studies, to stratify the cancer
cohorts into subcohorts based on more available data
on the stage of cancer, and/or other comorbidities, to
improve the accuracy of the survival estimates. For
example, because more than one-half of the patients
with prostate cancer in Taiwan were detected at
advanced ages and earlier stages based on the Cancer
Registry Annual Report (1999–2004) [28], the fre-
quent comorbidity and mixing of different stages in the
same cohort may make the extrapolation of survival
rates less accurate. Furthermore, if the data regarding
quality of life at each duration to date for cancer could
be collected, they could also be integrated with the
survival curves to obtain the quality-adjusted LE
[10,12,21,29], which could serve as the basis for
outcome evaluation in cost–utility analysis.
Regarding the choice between semiparametric and
parametric methods, one disadvantage of semiparamet-
ricmethods is that they are less efﬁcient than parametric
methods. Therefore, the standard errors of the Weibull
model were generally smaller than those of the Monte
Carlo method, as shown in Table 2, indicating a trade-
off between bias and efﬁciency for the two methods. In
fact, the Monte Carlo method is generally less biased
except for two cancers, skin and prostate, of which the
assumption of premature mortality might be violated.
Moreover, there is a general tendency of underestima-
tion for the Weibull model, as the relative biases are
all accompanied with a negative sign. In general, one
would consider the efﬁciency of estimation only if the
relative biases for different methods are very close or
similar. Thus, we recommend the Monte Carlo method
whenever the assumption of premature mortality seems
to hold in extrapolation of survival curves for cancer.
In conclusion, by incorporating information from
the life table of the general population, estimation using
the logit survival ratio extrapolation method is a robust
approach to calculating the lifetime survival of cancer
patients, as based on national data. The estimation of
average EYLL provides a quick overview of an indi-
vidual’s LE after diagnosis and potential loss of life due
to a speciﬁc type of cancer, as well as being helpful in the
outcome evaluation for cancer treatment and preven-
tion. To communicate the cancer risk with a lay person,
this would seem to be much more understandable than
simply giving the 5-year survival rate or cumulative
survival and could also be used directly to empower
people to engage in proactive prevention. The subtotal
of EYLL represents the greatest quantity that society
could possibly save by the prevention of the cancer. In
the future, the method could be integrated with quality
of life data for the comparative assessment of the out-
comes of cancer patients under different treatment pro-
tocols or different health-care plans for people to judge
the competitiveness [11,12,30].
Supplementary material for this article can be found on
http://www.ispor.org/publications/value/ViHsupplementary.
asp.
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